David Henry, MD, on Anticoagulants: Expert Perspective

2015 ASH Annual Meeting

David Henry, MD, of Pennsylvania Hospital, discusses new advances with direct oral anticoagulants, or DOACs.

Laurie H. Sehn, MD, MPH, on Classical HL: New Findings on the Need for Radiotherapy

Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Agency, discusses a study that showed patients with advanced-stage classical Hodgkin lymphoma, with a negative PET-scan following ABVD chemotherapy, have excellent outcomes without the need for consolidative radiotherapy, regardless of disease bulk at presentation (Abstract 579).

Multiple Myeloma

James N. Kochenderfer, MD

James N. Kochenderfer, MD, on Preventing Progressive Malignancy After Stem Cell Transplant

James N. Kochenderfer, MD, of the National Cancer Institute, discusses a clinical trial of allogeneic T cells expressing an anti-CD19 chimeric antigen receptor, which caused remissions of B-cell cancers after stem cell transplant, without causing graft-vs-host disease (Abstract LBA1).

Lymphoma

Julie Vose, MD, MBA, and David Straus, MD

Julie Vose, MD, MBA, and David Straus, MD, on Hodgkin Lymphoma Study Results: CALGB/Alliance 50604

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and David Straus, MD, of Memorial Sloan Kettering Cancer Center, discuss the initial results of the U.S. Intergroup Trial of response-adapted chemotherapy or chemotherapy/radiation therapy based on PET for nonbulky stage I and II Hodgkin lymphoma (Abstract 578).

Lymphoma

Olivier Casasnovas, MD

Olivier Casasnovas, MD, on Advanced-Stage Hodgkin Lymphoma: Interim Analysis of the Lysa Study

Olivier Casasnovas, MD, of Hôpital Le Bocage, discusses a phase III study comparing an early PET-driven treatment de-escalation to a not PET-monitored strategy in patients with advanced Hodgkin lymphoma (Abstract 577). To see the French language version of this video, please click here.

Multiple Myeloma

Julie Vose, MD, MBA, and Rafat Abonour, MD

Julie Vose, MD, MBA, and Rafat Abonour, MD, on Multiple Myeloma: The Path to a Cure

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Rafat Abonour, MD, of Indiana University Simon Cancer Center, discuss the session that he chaired on the question of whether researchers can design therapy that addresses the heterogeneity of the disease and eradicate most if not all of the myeloma clones.

Aug

Today In Oncology

David Henry, MD, on Anticoagulants: Expert Perspective

Related Videos

Laurie H. Sehn, MD, MPH, on Classical HL: New Findings on the Need for Radiotherapy

James N. Kochenderfer, MD, on Preventing Progressive Malignancy After Stem Cell Transplant

Julie Vose, MD, MBA, and David Straus, MD, on Hodgkin Lymphoma Study Results: CALGB/Alliance 50604

Olivier Casasnovas, MD, on Advanced-Stage Hodgkin Lymphoma: Interim Analysis of the Lysa Study

Julie Vose, MD, MBA, and Rafat Abonour, MD, on Multiple Myeloma: The Path to a Cure

Oral Nicotinamide May Offer Cost-Effective Prevention of Keratinocyte Carcinoma

When Diagnosis Waits: Lung Cancer, PET Access, and Global Oncology

Durvalumab Plus BCG Improves Outcomes in High-Risk Non–Muscle-Invasive Bladder Cancer

AMH Levels May Predict Adjuvant Chemotherapy Benefit in Premenopausal Women With Breast Cancer

WHO Calls for Action in New Status Report on Cancer